Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea

2015111 citationsJournal Articlegreen Open Access

Authors

CT-P13 was well tolerated and efficacious in patients with IBD.

Good health and well-being

Published in: Expert Review of Gastroenterology & Hepatology

Volume 9, Issue sup1, pp. 35-44

Field-Weighted Citation Impact: 10.25